greeksoup/ stock research
Stock research / Foreign companies / SNN · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Smith & Nephew plc (SNN)

Smith+Nephew is a medical technology company working on the repair, regeneration and replacement of soft and hard tissue. It has a 170-year history, serves around 100 countries and employs 16,988 people. It runs three global business units, Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management, supported by its own trained sales force. Figures are stated in US dollars. Sales by geography were $3,306m in the US, up 5.9%, $1,855m across other established markets, up 8.6% as reported and 5.9% underlying, and $1,003m in emerging markets, up 2.4%.

Smith & Nephew plc

Smith+Nephew is a medical technology company working on the repair, regeneration and replacement of soft and hard tissue. It has a 170-year history, serves around 100 countries and employs 16,988 people. It runs three global business units, Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management, supported by its own trained sales force. Figures are stated in US dollars. Sales by geography were $3,306m in the US, up 5.9%, $1,855m across other established markets, up 8.6% as reported and 5.9% underlying, and $1,003m in emerging markets, up 2.4%.

Orthopaedics

This is the largest unit at 40% of group sales, which were $2,437m in 2025 against $2,305m, up 5.7% as reported and 5.1% on an underlying basis. It covers hip, knee and shoulder replacement systems, robotics-assisted and digital surgical tools, and Trauma & Extremities products used to stabilise severe fractures and correct hard tissue deformities. Knee implants were $1,011m and Trauma & Extremities $649m, up 6.7% as reported. Segment trading profit was $363m against $265m, 36.9% higher. Hip implant performance came from the US launch of the CATALYSTEM Primary Hip System and growth in the OR30 Dual Mobility System, and the filing acknowledges a product gap as US market trends changed, with new introductions planned over the following 18 months.

Sports Medicine & ENT

This unit is 31% of group sales, at $1,934m in 2025 against $1,824m, up 6.0% as reported and 5.2% on an underlying basis. It sells products and instruments used to repair or remove soft tissue, and ear, nose and throat products. Sports Medicine Joint Repair was $1,067m, up 8.6% as reported. The unit's trading profit margin rose to 24.0%, which the filing attributes to operating leverage and productivity improvements.

Advanced Wound Management

This unit is 29% of group sales, at $1,793m against $1,681m, up 6.7% as reported and 5.6% on an underlying basis. It sells products and services for hard-to-heal wounds. Advanced Wound Care within it was $766m, up 4.3% as reported. The unit's trading profit margin rose to 24.9%, which the filing attributes to leverage from the sales growth.

Innovation and scale

The company states that it invested $296m in new innovation during 2025, and it launched 15 new products. It puts the markets it operates in at more than $50 billion a year, and says 15 million patients were treated with its products during the year. Its robotics platform is sold as CORI, described in the filing as one platform for all joints, and positioned for the shift of joint replacement out of hospital inpatient settings into ambulatory service centres. In ENT the company states that it intends to transform the standard of care with TULA.

The plan and the payout

The 12-Point Plan presented to investors in 2022 set the priorities for the three years to 2025, beginning with improving the performance of the Orthopaedics business, and 2025 was its final year. The interim dividend was 15.0 cents a share, taking the total distribution for the year to 39.1 cents a share. The filing notes the share price rose 28% during the year.

From Smith & Nephew's annual report on Form 20-F for the year ended 31 December 2025. That filing carries no Item 4 or Item 5 heading in its body, using a cross-reference index instead, so the annual report is read as one whole document rather than from separately located sections. The filing

Compare with another name

Smith & Nephew plc files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2025 it reported revenue of USD 6,164 million, up 6.1% on the year before. Its profit was USD 625 million, up 51.7%, and diluted earnings per share USD 0.72.

Smith & Nephew (SNN) in brief

Smith & Nephew (SNN) reported revenue of USD 6.2 billion for the year to 31 December 2025, up 6.1% on the year before.
Read moreProfit attributable to shareholders was USD 625 million and diluted earnings per share USD 0.72. Revenue was USD 5.8 billion in 2024, USD 5.5 billion in 2023, USD 5.2 billion in 2022 and USD 5.2 billion in 2021. Profit attributable to shareholders in the same years was USD 412 million, USD 263 million, USD 223 million and USD 524 million. Revenue grew 6.2% a year, compounded, over the five years to 2025. At the close of 10 November 2026 the market cap of Smith & Nephew was $13.6 billion, 21.6 times its earnings for 2025.

The share in the US

Last close$30.92 on 10 November 2026
52-week range$26.43 (2 October 2026) to $36.90 (27 February 2026)
Over one yeardown 7.3%
Market cap$13.6 billion: 877,724,845 shares outstanding at 31 December 2025 (20-F), each US share standing for 2 ordinary shares
P/E, latest fiscal year21.6: the last close over diluted EPS for the year to Dec 2025, USD 0.72 per ordinary share times 2, USD 1.43 per US share. The company reports once a year, so this is the latest fiscal year, not the last four quarters.

US dollars per share as it trades in the US; the market cap and the P/E are worked out here, not filed. Prices from IEX, for splits.

Ratios

From the latest annual report, the year to Dec 2025, in dollars

ROE11.8%
ROCE9.5%
Operating margin12.9%
Net margin10.1%
FCF marginn/a
Interest covern/a
Debt to equity0.59
Cash conversion2.06
Share count, last 12 months-0.7%
Sales CAGR, 3 years5.7%
Profit CAGR, 3 years41.0%
EPS$1.43

At the close of 10 November 2026

Price$30.92
Market cap$13.6 billion
Stock P/E21.59
Price to book2.57
EV / EBITDAn/a
Dividend yield2.4%
Market cap / sales2.20
52-week high$36.90
52-week low$26.43
Price, 1 year-7.3%
Price CAGR, 3 yearsn/a
Price CAGR, 5 yearsn/a
Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on the borrowings total Smith & Nephew plc states in its annual report, never added up from its parts; lease liabilities are a separate line. Nothing here is a valuation or a view.
SNNgreeksoup.ai
Daily prices to 10 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. This company reports once a year, so every view here moves once a year, on the day each annual report was filed, and holds until the next. P/E is the close over the year's EPS per US share: the EPS as filed, times the 2 ordinary shares one US share stands for. Sales and margin are each year's revenue and its operating margin. EV/EBITDA, price to book and market cap to sales set the close against that year's balance sheet and its share count per US share. The dashed line is the median over the range shown. Drawn in your browser; the range and overlay you pick are remembered here only.

The public record on SNN

Dividends$330.0 million paid in cash dividends in FY2025
Filings84 in twelve months: 80 reports on Form 6-K, most often director/PDMR shareholding (14); holding(s) in company (13); total voting rights (12); notice of results (4); admission to trading (3)
Planned insider salesno Form 144 notice in twelve months
Options tapeput/call 0.24 by open interest at the 10 November 2026 close; the straddle prices a 31.6% move to 20 November 2026
13F holders297 funds reported a position for the quarter to 30 June 2026; largest River Road Asset Management, LLC
Congress0 House trades disclosed in six months
Short interest4.4 million shares short, 3.71 days to cover at 30 October 2026

Income statement (profit and loss), 11 fiscal years

Year toDec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020 †Dec 2021Dec 2022 †Dec 2023 †Dec 2024Dec 2025
Revenue4,6344,6694,7654,9045,1384,5605,2125,2155,5495,8106,164
Cost of sales1,1431,2721,2481,2981,3381,3961,5431,5401,7301,7641,972
Gross profit3,4913,3973,5173,6063,8003,1643,6693,6753,8194,0464,192
Research and development222230223246292307356345339289296
Selling, general and administrative2,6412,3662,3602,4972,6932,5622,7202,8803,0553,1003,102
Operating profit628801934863815295593450425657794
Profit before tax5591,062879781743246586235290498779
Income tax149278112118143-20262.012.027.086.0154
Profit for the year410784767663600448524223263412625
Profit attributable to shareholders410784767663600448524223263412625
Filing20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F
USD million, from each year's annual report on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated. A year marked † shows the figure as the company restated it in a later annual report (Dec 2020, Dec 2022, Dec 2023); the first-filed figure is in the CSV. Profit attributable to shareholders is the profit for the year; the company reports no minority interests. Profit for the year includes the part that belongs to minority shareholders; profit attributable to shareholders is the part EPS is struck on. Each year links to its own page.
Year toDec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020 †Dec 2021Dec 2022 †Dec 2023 †Dec 2024Dec 2025
Diluted EPS0.460.880.880.760.600.510.600.260.300.470.72
Basic EPS0.460.880.880.760.690.510.600.260.300.470.72
Filing20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F

USD per ordinary share, as filed. One US-listed share can stand for more or fewer ordinary shares; the P/E above puts the two on the same basis.

Revenue by segment

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025Share
of the parts, latest year
Orthopaedics2,1072,1682,2221,9172,1562,1132,2142,3052,43739.5%
Sports Medicine & ENT1,4021,4611,5361,3331,5601,5901,7291,8241,93431.4%
Advanced Wound Management1,2561,2751,3801,3101,4961,5121,6061,6811,79329.1%
OrthopaedicsSports Medicine & ENTAdvanced Wound Management
4,765Dec 20175,138Dec 20195,212Dec 20215,549Dec 20236,164Dec 2025

USD million; hover a block for its figure and share

USD million, from the latest 20-F, in the company's own words. A year is shown only where the parts add up to the revenue above.

Revenue by product or service

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025Share
of the parts, latest year
Orthopaedics, Sports Medicine and Ear Nose and Throatn/an/a3,5093,6293,7583,2503,7163,7033,9434,1294,37070.9%
Advanced Wound Managementn/an/a1,2561,2751,3801,3101,4961,5121,6061,6811,79429.1%
Advanced Wound Bioactives344342n/an/an/an/an/an/an/an/an/an/a
Advanced Wound Care755719n/an/an/an/an/an/an/an/an/an/a
Advanced Wound Devices167172n/an/an/an/an/an/an/an/an/an/a
Arthroscopic Enabling Technologies604597n/an/an/an/an/an/an/an/an/an/a
Hip Implants205214n/an/an/an/an/an/an/an/an/an/a
Knee Implants631631n/an/an/an/an/an/an/an/an/an/a
Other Surgical Businesses548587n/an/an/an/an/an/an/an/an/an/a
Sports Medicine Joint Repair883932n/an/an/an/an/an/an/an/an/an/a
Trauma & Extremities497475n/an/an/an/an/an/an/an/an/an/a
Orthopaedics, Sports Medicine and Ear Nose and Throat FY2017 to FY2025Advanced Wound Management FY2017 to FY2025Sports Medicine Joint Repair FY2015 to FY2016Advanced Wound Care FY2015 to FY2016Knee Implants FY2015 to FY2016Arthroscopic Enabling Technologies FY2015 to FY2016Other Surgical Businesses FY2015 to FY2016Trauma & Extremities FY2015 to FY2016Advanced Wound Bioactives FY2015 to FY2016Other
4,634Dec 20154,765Dec 20175,138Dec 20195,212Dec 20215,549Dec 20236,164Dec 2025

USD million; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

USD million, from the latest 20-F, in the company's own words. A year is shown only where the parts add up to the revenue above.

Cash flow statement

Year toDec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020 †Dec 2021Dec 2022 †Dec 2023 †Dec 2024Dec 2025
Cash from operations1,0308491,0909311,1689358774686089871,285
Cash from investing-429-383-543-378-1,251-606-691-472-448-569-406
Cash from financing-558-529-434-3717.01,164-645-926-200-86.0-955
Depreciation and amortisation445415435427n/an/an/an/an/an/an/a
Buybacks77.036852.048.063.016.0n/a158n/an/a502
Dividends paid272279269321318328329327327327330
Filing20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F
USD million, from the cash flow statement as filed.
Read morePurchase of property, plant and equipment is the cash line as filed; purchases of intangible assets and acquisitions are not in it. Free cash flow is cash from operations less that purchase, arithmetic on the two filed lines. Cash from investing and from financing are the company's own section totals, below zero where cash went out. Buybacks are the cash paid for the company's own shares.

Balance sheet at year end

Year toDec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020 †Dec 2021Dec 2022 †Dec 2023 †Dec 2024Dec 2025
Funded by
Equity attributable to shareholders3,9663,9584,6444,8745,1415,2795,5685,2595,2175,2655,289
Borrowings, as filedn/a1,6501,4501,4651,8773,4863,1422,6762,8853,1253,111
Lease liabilitiesn/an/an/an/a17034.07.0196199196216
Other liabilities3,2011,7361,7721,7202,1112,2132,2031,8351,6861,7681,841
Total equity and liabilities7,1677,3447,8668,0599,29911,01210,9209,9669,98710,35410,457
Owned
Property, plant and equipmentn/a9821,0491,0621,3231,4491,5131,4551,4701,4221,638
Goodwilln/a2,1882,3712,3372,7892,9282,9893,0312,9923,0263,108
Other intangible assetsn/a1,4111,3711,2101,5671,4861,3981,2361,1101,032882
Cash and cash equivalents10238.01553332571,7511,285350302619557
Trade and other receivables1,1381,1851,2581,3171,3281,1161,1841,2641,3001,3811,413
Inventories1,2171,2441,3041,3951,6141,6911,8442,2052,3952,3872,117
Other assets4,710296358405421591707425418487742
Total assets7,1677,3447,8668,0599,29911,01210,9209,9669,98710,35410,457
Filing20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F
USD million, at each fiscal year end.
Read moreBoth totals are the company's own; other liabilities and other assets are each total less the rows shown. Borrowings is the company's own stated total where it files one; it is never added up from its parts here.

Ratios on the filed lines

Year toDec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020 †Dec 2021Dec 2022 †Dec 2023 †Dec 2024Dec 2025
Gross margin75.3%72.8%73.8%73.5%74.0%69.4%70.4%70.5%68.8%69.6%68.0%
Operating margin13.6%17.2%19.6%17.6%15.9%6.5%11.4%8.6%7.7%11.3%12.9%
Net margin8.8%16.8%16.1%13.5%11.7%9.8%10.1%4.3%4.7%7.1%10.1%
Return on year-end equity10.3%19.8%16.5%13.6%11.7%8.5%9.4%4.2%5.0%7.8%11.8%
Effective tax rate26.7%26.2%12.7%15.1%19.2%-82.1%10.6%5.1%9.3%17.3%19.8%
Filing20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F

Arithmetic on the filed lines of the same year: margins over revenue, return on equity as profit attributable to shareholders over year-end equity, tax over profit before tax.

Questions

What was Smith & Nephew's revenue in 2025?

Smith & Nephew (SNN) reported revenue of USD 6.2 billion for the year to 31 December 2025, up 6.1% on the year before.

How much did Smith & Nephew earn in 2025?

Profit attributable to shareholders was USD 625 million for the year to 31 December 2025, and diluted earnings per share USD 0.72.

What is Smith & Nephew's P/E ratio?

At the close of 10 November 2026, Smith & Nephew traded at 21.6 times its earnings for 2025.

What is Smith & Nephew's market cap?

The market cap of Smith & Nephew was $13.6 billion at the close of 10 November 2026.

Peers: Medical Equipment

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Intuitive Surgical Inc. ISRG$156.0 billion54.4118.5%28.4%20.5%0.00n/a
Edwards Lifesciences Corp. EW$59.9 billion58.779.4%21.6%13.4%0.06n/a
Steris plc STE$25.0 billion30.5011.4%19.0%8.1%0.261.0%
Zimmer Biomet Holdings, Inc. ZBH$20.3 billion27.166.0%13.6%7.0%0.590.9%
Smith & Nephew plc SNN *$13.6 billion21.5911.8%12.9%6.1%0.592.4%
Align Technology Inc. ALGN$12.3 billion25.3911.4%14.9%4.4%0.00n/a
MSA Safety Inc. MSA$6.7 billion22.5021.1%20.2%8.1%0.781.2%
Establishment Labs Holdings Inc. ESTA$2.0 billionn/a-246.6%-6.6%38.3%17.17n/a
Enovis Corp. ENOV$1.6 billionn/a-35.3%-20.6%3.3%0.84n/a
Cadre Holdings, Inc. CDRE$1.5 billion35.5811.2%10.7%18.3%1.011.2%
Anteris Technologies Global Corp. AVR$572 millionn/a-47.7%-4,880.4%9.0%0.00n/a
Sanara MedTech Inc. SMTI$291 millionn/a-403.0%n/a12.9%5.85n/a
All 110 in Medical Equipment
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Intuitive Surgical Inc. ISRG$156.0 billion54.4118.5%28.4%20.5%0.00n/a
Medtronic plc MDT$130.1 billion25.0310.4%18.1%9.8%0.562.8%
Stryker Corp. SYK$123.4 billion34.5215.4%20.7%7.9%0.641.1%
3M Co. MMM$97.9 billion28.2285.7%18.8%1.7%3.631.6%
Boston Scientific Corp. BSX$64.8 billion18.9413.7%18.7%8.9%0.47n/a
Edwards Lifesciences Corp. EW$59.9 billion58.779.4%21.6%13.4%0.06n/a
Becton Dickinson & Co. BDX$57.9 billion64.043.9%9.6%-2.6%0.692.0%
Medline Inc. MDLN$53.8 billion59.444.9%5.7%n/a1.07n/a
GE HealthCare Technologies Inc. GEHC$37.8 billion17.6518.5%13.3%6.9%0.860.2%
Resmed Inc. RMD$32.9 billion21.3226.8%33.0%9.0%0.071.1%
Dexcom Inc. DXCM$29.8 billion31.3339.1%24.0%13.0%0.49n/a
Koninklijke Philips N.V. PHG *$29.3 billion29.318.2%8.0%-1.0%0.741.3%
West Pharmaceutical Services Inc. WST$28.8 billion46.3221.5%23.0%12.6%0.070.2%
Steris plc STE$25.0 billion30.5011.4%19.0%8.1%0.261.0%
Zimmer Biomet Holdings, Inc. ZBH$20.3 billion27.166.0%13.6%7.0%0.590.9%
Solventum Corp. SOLV$15.3 billion101.213.2%5.6%-2.8%1.05n/a
Glaukos Corp. GKOS$14.0 billionn/a-23.7%-25.5%46.9%0.00n/a
Baxter International Inc. BAX$13.7 billionn/a-11.1%-1.9%5.3%1.322.0%
Smith & Nephew plc SNN *$13.6 billion21.5911.8%12.9%6.1%0.592.4%
Penumbra Inc. PEN$12.7 billion80.959.9%12.1%17.0%0.00n/a
Align Technology Inc. ALGN$12.3 billion25.3911.4%14.9%4.4%0.00n/a
Cooper Companies, Inc. COO$12.1 billion21.696.8%12.8%4.7%0.31n/a
Insulet Corp. PODD$10.3 billion24.1127.2%18.4%26.5%0.61n/a
Globus Medical Inc. GMED$10.1 billion18.4911.6%21.6%13.4%0.00n/a
Bausch & Lomb Corp. BLCO$7.6 billionn/a-1.7%7.1%8.9%0.79n/a
MSA Safety Inc. MSA$6.7 billion22.5021.1%20.2%8.1%0.781.2%
Teleflex Inc. TFX$6.2 billion18.878.7%9.4%20.9%0.460.9%
Haemonetics Corp. HAE$5.6 billion54.8911.6%12.8%4.1%1.26n/a
Merit Medical Systems Inc. MMSI$5.3 billion33.039.2%13.5%9.1%0.42n/a
LivaNova plc LIVN$5.0 billion30.3814.3%10.7%11.7%0.22n/a
MiniMed Group, Inc. MMED$4.9 billionn/an/an/an/a0.00n/a
Heartflow, Inc. HTFL$4.8 billionn/a-42.3%-37.8%n/a0.00n/a
ICU Medical Inc. ICUI$4.6 billion76.242.8%5.1%-5.9%0.53n/a
Integer Holdings Corp. ITGR$4.3 billion42.496.0%8.2%-0.3%0.71n/a
Envista Holdings Corp. NVST$4.1 billion6.6820.5%25.4%9.8%0.46n/a
Pulse Biosciences, Inc. PLSE$4.0 billionn/a-45.6%-5,821.1%1,637.2%0.00n/a
Warby Parker Inc. WRBY$3.8 billion498.421.9%0.2%9.9%0.00n/a
TransMedics Group, Inc. TMDX$3.2 billion24.6426.2%11.9%28.5%0.930.0%
Axogen, Inc. AXGN$3.0 billionn/a-6.4%-5.2%24.3%0.00n/a
AtriCure, Inc. ATRC$2.9 billion187.452.8%2.9%13.8%0.11n/a
iRhythm Holdings, Inc. IRTC$2.9 billionn/a-21.8%-5.7%21.6%3.68n/a
UFP Technologies Inc. UFPT$2.4 billion31.9615.8%15.5%8.6%0.20n/a
Establishment Labs Holdings Inc. ESTA$2.0 billionn/a-246.6%-6.6%38.3%17.17n/a
Dentsply Sirona Inc. XRAY$1.9 billionn/a-8.9%-1.5%-1.4%1.626.6%
Lemaitre Vascular Inc. LMAT$1.8 billion28.7114.7%27.7%11.8%0.391.2%
Inspire Medical Systems, Inc. INSP$1.8 billion18.1212.2%1.8%-0.2%0.00n/a
Kestra Medical Technologies, Ltd. KMTS$1.8 billionn/a-67.4%-134.5%60.7%0.33n/a
Butterfly Network, Inc. BFLY$1.7 billionn/a-29.1%-46.9%39.3%0.000.0%
Enovis Corp. ENOV$1.6 billionn/a-35.3%-20.6%3.3%0.84n/a
Conmed Corp. CNMD$1.5 billion21.146.9%9.9%1.6%0.771.2%
National Vision Holdings, Inc. EYE$1.5 billion31.165.6%4.1%7.8%0.26n/a
Cadre Holdings, Inc. CDRE$1.5 billion35.5811.2%10.7%18.3%1.011.2%
NovoCure Ltd. NVCR$1.4 billionn/a-34.7%-17.2%12.9%0.56n/a
Procept BioRobotics Corp. PRCT$1.3 billionn/a-34.9%-33.6%17.5%0.16n/a
Tandem Diabetes Care Inc. TNDM$1.3 billionn/a-36.4%-2.4%6.8%4.47n/a
Staar Surgical Co. STAA$1.2 billion1,717,853,041,864,201,984.000.1%0.2%42.4%0.00n/a
Integra LifeSciences Holdings Corp. IART$1.1 billion85.441.2%4.4%0.8%1.71n/a
Si-Bone, Inc. SIBN$1.1 billionn/a-7.4%-7.6%14.0%0.190.0%
Iradimed Corp. IRMD$1.1 billion46.4322.5%32.3%11.0%0.000.9%
Alphatec Holdings, Inc. ATEC$1.1 billionn/an/a-3.6%15.3%n/an/a
Ceribell, Inc. CBLL$1.1 billionn/a-62.9%-69.8%31.3%0.17n/a
Artivion, Inc. AORT$999 millionn/a-3.9%2.3%14.0%0.81n/a
Bioventus Inc. BVS$942 million13.9723.8%9.7%3.9%0.96n/a
Beta Bionics, Inc. BBNX$898 millionn/a-20.7%-72.7%43.7%0.00n/a
Orthopediatrics Corp. KIDS$873 millionn/a-10.0%-9.4%16.1%0.31n/a
Delcath Systems, Inc. DCTH$699 million125.565.0%5.2%38.1%0.00n/a
Tactile Systems Technology Inc. TCMD$599 million25.8410.5%9.4%14.4%0.00n/a
Sight Sciences, Inc. SGHT$594 millionn/a-57.8%-29.5%16.2%0.83n/a
Anteris Technologies Global Corp. AVR$572 millionn/a-47.7%-4,880.4%9.0%0.00n/a
Avita Medical, Inc. RCEL$545 millionn/an/a-33.9%17.0%n/an/a
Angiodynamics Inc. ANGO$512 millionn/a-20.1%-11.2%8.2%0.00n/a
Mimedx Group, Inc. MDXG$490 millionn/a-9.1%-8.3%-22.8%0.00n/a
Shoulder Innovations, Inc. SI$458 millionn/a-28.2%-54.4%n/a0.13n/a
NeuroPace Inc. NPCE$435 millionn/a-160.9%-15.3%11.6%4.970.0%
Mobia Medical, Inc. MOBI$406 millionn/an/an/an/a0.05n/a
Carlsmed, Inc. CARL$404 millionn/a-52.9%-59.0%n/a0.20n/a
Cerus Corp. CERS$394 millionn/a-9.7%-1.0%n/a0.84n/a
Cytosorbents Corp. CTSO$364 millionn/an/a-34.7%3.1%n/an/a
Embecta Corp. EMBC$363 million4.33n/a21.9%-7.6%n/a7.2%
Orchestra BioMed Holdings, Inc. OBIO$352 millionn/a-731.8%-195.4%1,007.4%4.58n/a
SS Innovations International, Inc. SSII$322 millionn/a-23.3%-15.8%89.7%0.00n/a
CapsoVision, Inc. CV$320 millionn/a-226.6%-217.1%n/a0.00n/a
Treace Medical Concepts, Inc. TMCI$320 millionn/a-90.5%-24.4%-7.1%0.91n/a
InfuSystem Holdings, Inc. INFU$306 million33.9314.7%9.8%2.4%0.31n/a
Sanara MedTech Inc. SMTI$291 millionn/a-403.0%n/a12.9%5.85n/a
Orthofix Medical Inc. OFIX$290 millionn/a-10.5%-2.5%2.1%0.52n/a
ClearPoint Neuro, Inc. CLPT$281 millionn/a-132.5%-70.6%32.5%1.86n/a
Profound Medical Corp. PROF$281 millionn/a-76.4%-145.1%65.3%0.11n/a
Utah Medical Products Inc. UTMD$232 million22.228.6%28.4%-7.0%0.00n/a
Orasure Technologies Inc. OSUR$229 millionn/a-15.8%-43.8%-7.5%0.00n/a
PRO DEX Inc. PDEX$226 million19.4024.4%16.8%13.3%0.33n/a
Electromed, Inc. ELMD$225 million19.8022.7%19.5%14.1%0.00n/a
RxSight, Inc. RXST$205 millionn/a-20.9%-50.4%-14.3%0.00n/a
Anika Therapeutics, Inc. ANIK$180 millionn/a-1.3%-2.1%9.4%0.00n/a
TriSalus Life Sciences, Inc. TLSI$175 millionn/a-3,861.0%-63.0%15.4%47.60n/a
Edap TMS SA FOCL$167 millionn/a-104.3%-35.4%n/a0.99n/a
Inogen Inc. INGN$157 millionn/a-22.6%-11.6%-2.3%0.00n/a
Koru Medical Systems, Inc. KRMD$147 millionn/a-4.2%-1.3%18.4%0.02n/a
Apyx Medical Corp. APYX$125 millionn/a-87.6%-5.5%24.4%3.89n/a
Pulmonx Corp. LUNG$122 millionn/a-124.4%-44.4%-3.2%1.11n/a
SkinHealth Systems Inc. SKIN$103 millionn/a-32.8%2.4%-4.4%4.36n/a
Stereotaxis, Inc. STXS$103 millionn/a-182.3%-75.7%-5.5%0.00n/a
Lakeland Industries Inc. LAKE$92 millionn/a-21.4%-4.1%-0.4%0.23n/a
Neuraxis, Inc. NRXS$87 millionn/a-334.1%-186.2%94.3%0.06n/a
Outset Medical, Inc. OM$80 millionn/a-85.4%-51.2%1.6%1.18n/a
Lucid Diagnostics Inc. LUCD$77 millionn/a-478.3%-930.8%24.9%2.15n/a
NutriBand Inc. NTRB$71 millionn/a-130.7%-435.6%-37.3%0.00n/a
RenovoRx, Inc. RNXT$57 millionn/a-140.2%-489.0%n/a0.00n/a
Lensar, Inc. LNSR$57 millionn/a304.4%-3.3%1.6%0.17n/a
PAVmed Inc. PAVM$10 millionn/a-34.5%-23,841.1%-89.0%0.43n/a
14 companies share its SEC industry code (Orthopedic, Prosthetic & Surgical Appliances & Supplies); the rest are the names nearest in size in its wider industry, Medical Equipment, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

Annual reports on EDGAR

FormYear toFiled
20-F31 December 202516 March 2026EDGAR
20-F31 December 202410 March 2025EDGAR
20-F31 December 202311 March 2024EDGAR
20-F31 December 20226 March 2023EDGAR
20-F31 December 20217 March 2022EDGAR
20-F31 December 20201 March 2021EDGAR
20-F/A31 December 201925 September 2020EDGAR
20-F31 December 20192 March 2020EDGAR
20-F31 December 20184 March 2019EDGAR
20-F31 December 20175 March 2018EDGAR
20-F31 December 20166 March 2017EDGAR